ABBV SEC Filings
SEC filings for ABBV. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 8-K | Oct 16, 2026 | 0001104659-26-116227EDGAR |
| 8-KAIAbbVie expects Q3 2026 results to include $216 million of pre-tax acquired IPR&D and milestones expense, a $0.11 per share hit to both GAAP and adjusted diluted EPS. | Oct 5, 2026 | 0001551152-26-000030EDGAR |
| 8-KAIAbbVie Inc. announced the completion of its acquisition of Apogee Therapeutics, Inc. on September 3, 2026, disclosed via press release under Regulation FD. | Sep 3, 2026 | 0001104659-26-104940EDGAR |
| 8-K | Aug 18, 2026 | 0001104659-26-098367EDGAR |
| 8-K | Aug 5, 2026 | 0001104659-26-091269EDGAR |
| 8-K | Jul 31, 2026 | 0001551152-26-000023EDGAR |
| 8-KAIAbbVie disclosed that Q2 2026 GAAP and adjusted non-GAAP earnings will include $291 million in pre-tax acquired IPR&D and milestones expense, reducing diluted EPS by $0.17. | Jul 6, 2026 | 0001551152-26-000021EDGAR |
| 8-KAIAbbVie disclosed a definitive agreement to acquire Apogee Therapeutics, announced via a joint press release and investor presentation on June 22, 2026. | Jun 22, 2026 | 0001104659-26-076067EDGAR |
| 8-K | May 12, 2026 | 0001104659-26-059484EDGAR |
| 8-KAIAbbVie Inc. announced its financial results for the first quarter ended March 31, 2026 via a press release issued on April 29, 2026. | Apr 29, 2026 | 0001551152-26-000013EDGAR |
| 8-K | Apr 3, 2026 | 0001551152-26-000011EDGAR |
| 8-K | Mar 4, 2026 | 0001104659-26-023534EDGAR |
| 8-K | Feb 26, 2026 | 0001104659-26-020643EDGAR |
| 8-KAIAbbVie Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 via a press release issued on February 4, 2026. | Feb 4, 2026 | 0001551152-26-000004EDGAR |
| 8-KAIAbbVie disclosed that its Q4 2025 GAAP and adjusted non-GAAP earnings will include $1.3 billion of pre-tax acquired IPR&D and milestones expense, reducing diluted EPS by $0.71. | Jan 7, 2026 | 0001551152-26-000002EDGAR |
| 8-KAIAbbVie Inc. announced its financial results for the third quarter ended September 30, 2025 via a press release furnished as an exhibit to this 8-K filing. | Oct 31, 2025 | 0001551152-25-000047EDGAR |
SEC filings for companies related to ABBV
Never miss a ABBV filing.
Get an email when ABBV files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.